Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-09-15
2011-11-29
Wilson, James O (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S183000
Reexamination Certificate
active
08067450
ABSTRACT:
The present invention relates to thiazolidinedione analogues that are useful for treating hypertension, diabetes, and inflammatory diseases. Formula (I), wherein: each of R1and R4is independently selected from H, halo, aliphatic, and alkoxy, wherein the aliphatic and alkoxy are optionally substituted with 1-3 of halo; R2is halo, hydroxy, or optionally substituted aliphatic, and R′2is H, or R2and R′2together form oxo; R3is H; and Ring A is a phenyl.
REFERENCES:
patent: 4582839 (1986-04-01), Meguro et al.
patent: 4687777 (1987-08-01), Meguro et al.
patent: 4725610 (1988-02-01), Meguro et al.
patent: 5304212 (1994-04-01), Czeisler et al.
patent: 5441971 (1995-08-01), Sohda et al.
patent: 5886026 (1999-03-01), Hunter et al.
patent: 5929101 (1999-07-01), Colca
patent: 6099562 (2000-08-01), Ding et al.
patent: 6693106 (2004-02-01), Rahbar et al.
patent: 2007/0043094 (2007-02-01), Wizel et al.
patent: 2007/0078170 (2007-04-01), Khanduri et al.
patent: 2008/0319024 (2008-12-01), Greil et al.
patent: 2009/0137638 (2009-05-01), Colca et al.
patent: 2009/0143441 (2009-06-01), Colca et al.
patent: 2009/0143442 (2009-06-01), Colca et al.
patent: 0008203 (1980-02-01), None
patent: 0549365 (1993-06-01), None
patent: 0753298 (1997-01-01), None
patent: WO 86/02073 (1986-04-01), None
patent: WO 92/18501 (1992-10-01), None
patent: WO 01/00579 (2001-01-01), None
patent: WO 01/82916 (2001-11-01), None
patent: WO 02/088120 (2002-11-01), None
patent: WO 2004/007490 (2004-01-01), None
patent: WO 2004/101561 (2004-11-01), None
patent: WO 2006/035954 (2006-04-01), None
patent: WO 2007/109024 (2007-09-01), None
patent: WO 2007/109037 (2007-09-01), None
patent: WO 2007/109088 (2007-09-01), None
patent: WO 2009/038681 (2009-03-01), None
patent: WO 2010/105048 (2010-09-01), None
Blocker, <http://dictionary.reference.com/browse/blocker>, accessed Apr. 6, 2011.
Diuretic, <http://www.medterms.com/script/main/art.asp?articlekey=7103>, accessed Apr. 6, 2011.
Inhibitor, <http://www.biology-online.org/dictionary/Inhibitor>, accessed Apr. 6, 2011.
Statin, <http://www.answers.com/topic/statin>, accessed Apr. 6, 2011.
Sohda, T., et al., “Studies on Antidiabetic Agents. II. Synthesis of 5-[4-(1-Methylcyclohexylmethoxy)-benzyl]thiazolidine-2,4-dione (ADD-3878) and Its Derivatives”, Chemical and Pharmaceutical Bulletin, Pharrnaceutical Society of Japan, Tokyo, (1982) vol. 30, No. 10.
Colca, Jerry R., “Insulin sensitizers may prevent metabolic inflammation”, Biochemical Pharmacology, Pergamon, Oxford, GB, vol. 72, No. 2, Jul. 14, 2006, pp. 125-131.
Colca, Jerry R., et al., “Identification of a Novel Mitochondrial Protein (“mitoNEET”) cross-linked specifically by a thiazolidinedione photoprobe”, American Journal of Physiology, Endocrinology and Metabolism, Feb. 2004, vol. 286, No. 2, pp. E252-E260.
International Search Report for PCT/US2008/010723 dated Mar. 2, 2009.
International Search Report for PCT/US2010/026971 dated Jul. 22, 2010.
International Search Report for PCT/US2010/060439 dated May 23, 2011.
International Search Report for PCT/US2010/060449 dated Mar. 7, 2011.
International Search Report for PCT/US2010/060453 dated Mar. 28, 2011.
International Search Report for PCT/US2010/060459 dated Mar. 2, 2011.
Agarwal, R., “Anti-Inflammatory Effects of Short-Term Pioglitazone Therapy in Men with Advanced Diabetic Nephropathy”, American Journal of Physiology-Renal Physiology, vol. 290, No. 3 (2006). pp. F600-F605.
Berge, S.M., “Pharmaceutical Salts”, Journal Pharmaceutical Sciences, vol. 66, No. 1 (1977), pp. 1-19.
Campbell, I.W., “Pioglitazone-An Oral Antidiabetic Agent and Metabolic Syndrome Modulator, Can Theory Translate into Practice?”, British Journal of Diabetes and Vascular Disease, Medinews, GB vol. 5, No. 4 (2005), pp. 205-210.
Carpenter, Donald, E., et al., “Process Development and Scale-Up of the Potential Thiazolidinedione Antidiabetic Candidate PNU-91325”, Organic Process Research and Development, American Chemical Society, (2002), vol. 6, pp. 721-727.
Colca, J.R., “What has Prevented the Expansion of Insulin Sensitisers?”, Expert Opinion on Investigational Drugs, 2006, United Kingdom, vol. 15, No. 3 (2006), pp. 205-210.
Feinstein, D.L., “Receptor-Independent Actions of PPAR Thiazolidinedione Agonists: Is Mitochondrial Function the Key?” Biochemical Pharmacology, Pergamon, Oxford, GB, vol. 70, No. 2 (2005), pp. 177-188.
Freireich, D.L., “Quantative Comparisons of Toxicity of Anticancer Agents in Mouse, Rate, Hamster, Dog, Monkey and Man”, Cancer Chemotherapy Reports, vol. 50, No. 4 (1966), p. 219-244.
Geldmacher, D.S., “Pioglitazone in Alzheimer's Disease: Rationale and Clinical Trial Design”, Neurobiology of Aging, Tarrytown, NY, US, vol. 25 (2004), pp. S211-S212.
Gerber, P., “Effects of Pioglitazone on Metabolic Control and Blood Pressure: A Randomized Study in Patients with Type 2 Diabetes Mellitus”, Current Medical Research and Opinion, Hants, GB, vol. 19, No. 6 (2003), pp. 532-539.
Harrigan, George G., “PNU-91325 Increases Fatty Acid Syntheses from Glucose and Mitochondrial Long Chain Fatty Acid Degradation: A Comparative Tracer-Based Metabolomics Study with Rosiglitazone and Piolitazone in hepG2 Cells”, Metabolomics, Kluwer Academic Publishers-Plenum Publishers, NE, vol. 2, No. 1 (2006) pp. 21-29.
Hofmann, C., “Glucose Transport Deficiency Corrected by Treatment with the Oral Anti-Hyperglycemic Agent Pioglitazone”, Endocrinology, 129 (1991), pp. 1915-1925.
Kulkarmi, S.S., “Three-Dimensional Quantitative Structure Activity Relationship (3-D-QSAR) of Antihyperglycemic Agents” Bioorganic & Medicinal Chemistry, Elsevier Science Ltd, GB, vol. 7 (1999), pp. 1475-1485.
Lehmann, J.M., “An Antidiabetic Thiazolidinedione is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor (PPAR)”, J. Biol Chem, 270 (1995) p. 12953.
Matsusue, K., “Liver Specific Disruption of PPAR in Leptin-Deficient Mice Improves Fatty Liver but Aggravates Diabetic Phenotypes”, J. Clim. Invest., 111 (2003), p. 737.
Oguchi, M., et al., “Molecular Design, Synthesis, and hypoglycemic Activity of a Series of Thiazolidine-2, 4-diones”, Journal of Medicinal Chemistry, (2000)vol. 43 No. 16, pp. 3052-3066.
Pershadsingh, H., “Effect of Pioglitazone Treatment in a patient with Secondary Multiple Sclerosis”, Journal of Neuorinflammation Biomed Central Ltd, London, GB, vol. 1, No. 1 (2004), p. 3.
Pershadsingh, H., “Peroxisome Proliferator-Activated Receptor-Gamma: Therapeutic Target for Diseases Beyond Diabetes: Quo Vadis?” Expert Opinion on Investigational Drugs, vol. 13, No. 3 (2004), pp. 215-228.
Sohda, T., “Studies on Antidiabetic Agents. Synthesis and Hypolglycemic Activity of 5-[4-(Pyridylalkoxy)Benzyl]-2,4-Thiazolidinediones”, Arzneimittel Forshung Drug Research, ECV Editio. Cantor Verlag, Aulendoef, DE, vol. 40, No. 1 (1990), pp. 37-42.
Tanis, S. et al., “Synthesis and Biological Activity of Metabolites of the Antidiabetic, Antihyperglycemic Agent Pioglitazone”, Journal of Medicinal Chemistry, American Chemical Society, (1996), vol. 39, pp. 5053-5063.
Vosper, H., “The Peroxisome Proliferators Activated Receptor D is Required for the Differentiation of THP-1 Moncytic Cells by Phorbol Ester”, Nuclear Receptor, I (2003), p. 9.
Willi, S.M., “Effective Use of Thiazolidinedione for the Treatment of Glucocorticoid-Induced Diabetes”, Diabetes Research and Clinical Practice, vol. 58, No. 2 (2002), pp. 87-96 & pp. 91-94.
Yamamoto, S., “Effects of Pioglitazone on Steroid-Induced Diabetes Mellitus”, Journal of the Japan Diabetes Society, vol. 47, No. 8, pp. 643-648, (2004).
International Search Report for PCT/US2007/006321, dated Aug. 10, 2007.
International Search Report for PCT/US2007/006385, dated Aug. 31, 2007
Int
Colca Gerard R.
Gadwood Robert C.
Parker Tim
Cheng Karen
Honigman Miller Schwartz and Cohn LLP
Metabolic Solutions Development Company
O'Brien Jonathan P.
Weber Andrew N.
LandOfFree
Thiazolidinedione analogues for the treatment of metabolic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thiazolidinedione analogues for the treatment of metabolic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thiazolidinedione analogues for the treatment of metabolic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4307055